ABVC BioPharma
ABVC
5 hedge funds and large institutions have $1.66M invested in ABVC BioPharma in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
42% more capital invested
Capital invested by funds: $1.17M → $1.66M (+$488K)
25% more funds holding
Funds holding: 4 → 5 (+1)
3.34% more ownership
Funds ownership: 1.5% → 4.84% (+3.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$2.21M |
| 2 |
BlackRock
New York
|
+$78.9K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$12.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$4K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$3K |
ABVC Hedge Fund Activity: Q2 2022 in Review
5 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q2 2022, worth a combined $1.66M — up 42% from $1.17M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ABVC positions and 2 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $2.21M. The largest seller was Morgan Stanley, exiting entirely with an estimated $4K sold.
- 5 institutional investors held ABVC BioPharma (ABVC) as of Q2 2022, up from 4 in Q1 2022.
- Funds reported $1.66M of ABVC BioPharma stock for Q2 2022, up 42% quarter-over-quarter.
- 3 funds opened new ABVC BioPharma positions in Q2 2022 and 2 closed out, a net change of +1 holder.
- The largest ABVC BioPharma buyer in Q2 2022 was Armistice Capital, an estimated $2.21M added.
- The largest ABVC BioPharma seller in Q2 2022 was Morgan Stanley, an estimated $4K sold.
Based on aggregated 13F filings for Q2 2022.